Sinopharm
Sinopharm, a major state-owned enterprise and one of China’s leading pharmaceutical and healthcare providers, has made a significant leap in global brand rankings. According to the Healthcare 2025 report by Brand Finance, Sinopharm’s brand value rose by 6% to USD 3.8 billion, propelling it up 13 spots to become the fourth strongest pharmaceutical brand worldwide. It now holds a Brand Strength Index (BSI) score of 74.4/100 and has seen its brand rating upgraded from AA- to AA. This remarkable rise is attributed to Sinopharm’s strong domestic reputation and increasing brand recognition, reinforcing its dominant position in China’s healthcare industry.
"Sinopharm has climbed 13 places to become the world’s fourth strongest pharma brand, with a brand value of USD 3.8 billion and a BSI score of 74.4—driven by its strong reputation and growing influence in China’s healthcare sector."
Sinopharm: World’s Fourth Strongest Pharma Brand for 2025
Sinopharm has emerged as the world’s fourth strongest pharmaceutical brand for 2025, marking one of the most impressive climbs in this year’s rankings. With its brand value up by 6% to USD 3.8 billion and a Brand Strength Index (BSI) score of 74.4/100, Sinopharm advanced 13 places to achieve an upgraded AA rating.
The company’s remarkable rise reflects its solid reputation, brand admiration, and leadership in China’s healthcare landscape. Moving beyond its pivotal role in global COVID-19 vaccine development, Sinopharm’s 2025 momentum is defined by strategic partnerships, innovation, and global expansion.
Key highlights reinforcing its brand strength include:
Sinopharm's Market revenue
Sinopharm experienced steady revenue growth up to 2023; however, 2024 marked a significant downturn. The year proved challenging, with notable revenue and operating profit declines, reflecting wider pressures within the healthcare sector. The revenue drop in 2024 was driven by several factors, including stagnation in the pharmaceutical distribution market, difficulties in working capital management, and reduced medical device distribution segment turnover. Additionally, the company was impacted by broader market dynamics and ongoing service transformation within the healthcare industry. In the first half of 2025, there was a slight decrease in total assets by 0.37% and a modest increase in net assets attributable to shareholders by 2.02%. Revenue grew by 3.54% compared to the same period last year, while total profit and net profit attributable to shareholders declined by 6.92% and 5.19% respectively. The company also reported a negative net cash flow from operating activities, indicating potential cash management challenges. These financial indicators suggest a mixed performance, with revenue growth but a decline in profitability, which may impact the company’s market positioning and stakeholder confidence.
"After steady growth through 2023, Sinopharm faced a sharp downturn in 2024, with profitability under pressure despite modest revenue growth in early 2025."
Seven-year market revenue of Sinopharm (2019-2025)
Fig 8: Market revenue of Sinopharm
An Overview of Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd. was founded in Shanghai in January 2003 and listed on the Hong Kong Stock Exchange (01099.HK) in September 2009. The group now comprises over 1,100 subsidiaries, including two A-share listed companies: Sinopharm (CNCM LTD) and Sinopharm Accord.
Since its inception, under the guidance of CNPGC, Sinopharm has aligned closely with national policies and industry trends, driving the transformation and integration of China’s pharmaceutical distribution sector and emerging as a market leader. The company has established a fully integrated supply chain ecosystem centered on pharmaceutical and medical device distribution, while also extending into pharmaceutical manufacturing, medical devices, chemical reagents, and related fields. Today, Sinopharm is a leading distributor and retailer of pharmaceuticals, medical devices, and healthcare products, as well as a top supply-chain service provider in China.
In 2024, Sinopharm achieved revenue of RMB 584.5 billion. Its pharmaceutical distribution business strengthened its leadership, serving over 700,000 customers across provinces, autonomous regions, and municipalities, while steadily expanding market share. The medical device business demonstrated strong network coverage, enhanced comprehensive service capabilities, and promoted industrial manufacturing. The retail network continued to optimize operations, now encompassing over 10,000 pharmacies, with traditional and speciality outlets maintaining steady growth. Sino Biopharmaceutical Limited reported strong financial results for the first half of 2025, with revenue reaching RMB 17.57 billion, representing a 10.7% increase year-on-year. The Chinese pharmaceutical conglomerate's profit attributable to owners from continuing operations surged 140.2% to RMB3.39 billion, driven by strong revenue growth and increased investment returns.
Guided strategically by CNPGC, Sinopharm remains committed to its role as a centrally-administered pharmaceutical enterprise, advancing the “Healthy China” strategy, safeguarding public health, and meeting the growing demand for quality healthcare services.
Sinopharm Group strategic collaboration with Sino Biopharm
China Biopharmaceutical, affiliated with Sino Biopharm through its subsidiary Chia Tai Tianqing (CP Tianqing), entered into a strategic cooperation agreement with Sinopharm Group aimed at strengthening retail drug distribution across China. The agreement was signed in Chengdu and focuses on integrating Sinopharm Group’s National University Pharmacy and SPS+ professional pharmacy resources with China Biopharmaceutical’s extensive product portfolio. Through this collaboration, both companies plan to expand their presence in the off-hospital market, establish a nationwide retail network, and enhance patient access and convenience in purchasing medicines.